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Can Statins Reduce Perioperative Morbidity and Mortality in Patients
Undergoing Non-Cardiac Vascular Surgery?
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Aims. To determine whether statins can reduce perioperative morbidity and mortality in patients undergoing non-cardiac
vascular surgery.
Methods. A search using Pubmed was performed to identify reports in English. The search terms were: ‘‘statins’’,
‘‘perioperative morbidity’’, ‘‘perioperative mortality’’ and ‘‘vascular surgery’’. We excluded studies dealing with the effect
of statins in cardiac surgery. Retrieved articles were manually searched.
Results. Current evidence shows that statins decrease perioperative morbidity and mortality in patients undergoing non-
cardiac vascular surgery. Any benefit probably occurs soon (within a month) after initiating treatment.
Conclusions. Appropriately designed trials need to confirm the beneficial effect of perioperative statin therapy in various
patient categories. The optimal duration and dose of perioperative statin therapy should be defined.
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The prevalence of vascular complications is as high as
5.6% in non-cardiac operations.1 Therefore, as many
as 1 million surgical procedures may be complicated
by perioperative vascular events every year.2 Com-
plications, such as atrial fibrillation,3e4 ventricular
arrhythmias,5 pulmonary edema6 and myocardial in-
farction (MI),6e8 are the main causes of increased peri-
operative,7,8 as well as long-term,9 morbidity and
mortality in patients undergoing major elective non-
cardiac surgery. Postoperative myocardial ischaemic
events are common in high-risk patients (e.g. those
with coronary heart disease) undergoing non-cardiac
surgery.10 Lee et al. analyzed the risk of major cardiac
complications (MI, cardiogenic pulmonary edema,
cardiac arrest and cardiac death) in 4315 patients
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predict major cardiac complications and cardio-
vascular death in patients undergoing non-cardiac
surgery,12 but its classification of procedures seems
suboptimal.
MI is a cause of perioperative morbidity and
mortality after vascular surgery2,13 that may remain
unrecognised.11,14e16 Although the incidence of peri-
operative MI among patients undergoing major
non-cardiac surgery is 2e3%, rates among those
undergoing major vascular surgery can reach
34%.7,16 Endovascular surgery may be associated
with reduced perioperative complications compared
with open surgery, although this does not apply
to late cardiac events.17 Perioperative MI is also asso-
ciated with prolonged hospital stay and morbidity
and mortality rates as high as 25e40%.18,19
Various drugs may reduce vascular events in pa-
tients undergoing major elective vascular surgery.
These include beta-blockers,7,8,20e25 calcium-channel
blockers,26 a2-adrenergic agonists,
27e29 and aspirin.30
However, no globally accepted guidelines have been
formulated.31 It follows that patients undergoing elec-
tive vascular surgery are often underprotected.32rved.
287Statins and Perioperative Morbidity and MortalityStatins can stabilize coronary plaques,33e36 and ex-
ert anti-inflammatory antithrombogenic, antiprolifer-
ative and leucocyte-adhesion inhibiting effects.37e44
Therefore, statins can prevent vascular complica-
tions,45 possibly cost-effectively.46
Methods
We searched PubMed for studies in English using the
terms ‘‘statins’’, ‘‘perioperative morbidity’’, ‘‘peri-
operative mortality’’ and ‘‘vascular surgery’’. We
excluded articles dealing with cardiac surgery or
percutaneous intervention. The relevant articles were
manually searched for additional studies.
Results
Perioperative statin therapy and
morbidity/mortality rates
Trials that investigated the effect of perioperative sta-
tin therapy on morbidity and mortality in patients un-
dergoing non-cardiac vascular surgery are shown in
Table 1.
In a retrospective case-control study including 2816
patients undergoing major non-cardiac vascular sur-
gery (acute or elective abdominal aortic aneurysm re-
pair, carotid endarterectomy [CEA], lower extremity
revascularization),47 perioperative statin use was as-
sociated with a> 4-fold reduced risk in perioperative
mortality [adjusted odds ratio (OR)¼ 0.22, 95% confi-
dence interval (CI)¼ 0.10e0.47]. This finding was
supported by a prospective, randomized, placebo-
controlled, double-blind trial assessing the effect of
atorvastatin (20 mg/day) for 45 days on perioperative
cardiovascular events after vascular surgery com-
pared with placebo.48 Vascular surgery was per-
formed not earlier than 2 weeks after randomization
(average 31 days after starting medication). All
patients were followed for 6 months after surgery. De-
spite the small number of patients (50/group), a more
than three-fold risk reduction was observed for statin
users vs. placebo (8.0% vs. 26.0%, p¼ 0.031). The rate
of combined end points (death from cardiac causes,
nonfatal acute MI, ischemic stroke and unstable angina)
was 9.1% in the atorvastatin group and 28.3% in the
placebo group ( p¼ 0.030).
The beneficial effect of statins and non-statin lipid-
lowering agents was reported in a large, retrospective
cohort study including 780 591 patients undergoing
major non-cardiac surgery.49 Of these, 65 399 patients
underwent vascular surgery; 13 862 patients werestatin users. Statin use was associated with a signifi-
cant ( p< 0.001) reduction in perioperative mortality
in patients undergoing not only vascular, but also
any non-cardiac surgery.
A study [Statins for Risk Reduction in Surgery
(StaRRS)] assessing the effect of statins on cardiac
complications (death, MI, myocardial ischemia, ven-
tricular tachyarrhythmias and acute congestive heart
failure) in patients undergoing non-cardiac vascular
surgery (CEA, aortic surgery, or lower extremity re-
vascularization) supported the use of perioperative
statin therapy.50 Complications occurred in 157 of
1163 eligible hospitalizations. A multivariate model
(accounting for age, gender, body mass index, type
of operation, whether surgery was urgent or elective,
diabetes mellitus and left ventricular dysfunction)
showed that statins were beneficial (OR¼ 0.52, 95%
CI¼ 0.35e0.76, p¼ 0.001).
Another trial included 1566 patients undergoing
CEA (1440 patients) or CEA combined with coronary
artery bypass grafting (CABG, 126 patients). Peri-
operative statin (20 10 mg/day atorvastatin [332
patients], 20 10 mg/day simvastatin [189 patients],
30 20 mg/day pravastatin [91 patients], 30 10
mg/day lovastatin [32 patients] or 30 10 mg/day
fluvastatin [13 patients]) use in 657 (42%) patients
significantly reduced the incidence of cerebrovascular
events and mortality.51 In multivariate analysis,
adjusting for comorbidities associated with stroke
(symptomatic carotid artery disease, chronic atrial
fibrillation, hyperlipidemia, intraluminal shunt and
patch graft use and combined CEA/CAGB),
statin use was associated with reduced odds of peri-
operative stroke (OR¼ 0.29, 95% CI¼ 0.14e0.61,
p< 0.05).51 Similarly, in multivariate analysis of peri-
operative mortality, adjusting for comorbidities (per-
centage carotid stenosis, hypertension, chronic atrial
fibrillation, coronary artery disease, congestive heart
failure, chronic renal insufficiency, use of b-blockers,
and combined CEA/CABG), statins reduced peri-
operative death (OR¼ 0.14, 95% CI¼ 0.03e0.62,
p< 0.05).51 An observational study verified the protec-
tive effect of statins in patients undergoing CEA
(Table 1).52 However, as the authors underlined, these
results need to be confirmed in randomized controlled
trials.
The long-term benefit of statins was reported in pa-
tients undergoing successful abdominal aortic aneu-
rysm (AAA) surgery.53e55 A 6.3% risk for cardiac
death and MI at 2 years,54 and a 28% incidence for
death due to cardiovascular causes at 8 years55 follow-
ing aortic operations have been reported. After a me-
dian follow-up of 4.7 years, patients using statins (154
of 510 followed-up patients) had a 2.5-fold reductionEur J Vasc Endovasc Surg Vol 32, September 2006
Table 1. Trials assessing the effect of statin therapy on perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery
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After a median follow-up of 4.7
years (interquartile range, 2.7 to 7.3
years), statin use was shown to be
associated with a 2.5-fold reduction
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(HR¼ 0.4; 95% CI: 0.3e0.5) and more
than a threefold reduction in the risk
of cardiovascular mortality (HR¼ 0.3;
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290 K. I. Paraskevas et al.in all-cause mortality (hazard ratio [HR]¼ 0.4; 95%
CI¼ 0.3e0.5) and more than a threefold reduction in
the risk of vascular mortality (HR¼ 0.3; 95% CI:
0.2e0.6) compared with non-users (356 of 510
followed-up patients).53 In the same study, use of b-
blockers was also associated with an approximately
1.5-fold reduction in all-cause and vascular mortality
compared with non-use thus verifying the results of
another study,51 although an opposite opinion was
also expressed.56 The authors concluded that statin
use in patients undergoing successful AAA surgery
is associated with a significant reduction in all-cause
and vascular mortality. Similar results regarding
long-term survival were obtained from preoperative
statin therapy in patients undergoing infrainguinal
vascular bypass surgery57 in addition to improved
graft patency.58
A beneficial effect from using both b-blockers and
statins on perioperative (30-day) mortality and non-
fatal MI in patients undergoing AAA surgery was
demonstrated.59 In multivariate analysis, patients re-
ceiving both medications showed a 4-fold and 3-fold
reduction in perioperative mortality and nonfatal MI
following AAA surgery, respectively, compared with
patients receiving either statins (7.7% vs. 33%,
OR¼ 0.24, 95%CI¼ 0.10e0.70, p¼ 0.01) or b-blockers
(7.7% vs. 20%, OR¼ 0.24, 95%CI¼ 0.11e0.54, p¼ 0.01)
alone. These results59 suggest a benefit of combining
statins and b-blockers in high-risk patients as defined
by a revised cardiac index. The opinion that combined
treatment for vascular risk factors results in increased
benefit has been reported.60e61
A prospective, randomized trial (the Dutch Echo-
cardiographic Cardiac Risk Evaluation Applying
Stress Echo e IV [DECREASE-IV] Study) is under
way.62 It will determine the impact of perioperative
administration of a b-blocker (bisoprolol), a statin (flu-
vastatin), or both, on 30-day vascular events (includ-
ing non-fatal MI or any death with a cardiovascular
cause: cardiac arrest, MI, pulmonary embolus, stroke,
hemorrhage, or death due to unknown causes) follow-
ing major non-cardiac surgery.
Statins and peripheral arterial disease (PAD)
In patients with PAD, statins improve lower extremity
blood flow and lower extremity function (as defined
by ankle brachial index),63e64 as well as subjective
symptoms of claudication (e.g. walking time).65e68
In addition, a retrospective review57 of infrainguinal
vascular bypass surgery in 446 patients showed that
preoperative statin use was associated with fewer car-
diovascular complications (6.9% vs. 20.1%; p< 0.008)Eur J Vasc Endovasc Surg Vol 32, September 2006and a shorter in-hospital stay compared with non-
users (6.4 vs. 9.7; p¼ 0.007). Statin use was a predictor
of fewer preoperative combined vascular complica-
tions in multivariate analysis (OR¼ 0.36, 95% CI¼
0.14e0.93, p¼ 0.035).
The results that derive from statin use57 are better
compared with the results that derive from perioper-
ative b-blockade use in patients undergoing infrarenal
vascular surgery.24 In this double-blind, randomized,
placebo-controlled trial the effect of perioperative
b-blockade with metoprolol vs. placebo on patients
undergoing infrarenal vascular surgery was investi-
gated.24 Metoprolol use did not reduce 30-day cardio-
vascular events (MIs, unstable angina, ventricular
tachycardia, stroke) compared with placebo [Adjusted
(for sex, age, baseline use of statins and planned aortic
cross-clamping) RR¼ 0.87 (0.48e1.55)]. However,
metoprolol significantly reduced the median (95%
CI) time between surgery and discharge compared
with placebo (9 [8e12] vs. 12 [9e19]) days (adjusted
[for sex, age, baseline use of statins and planned use
of aortic cross-clamping] HR¼ 1.71, 95% CI¼ 1.09e
2.66, p¼ 0.02).
It has been suggested that statins exert a renopro-
tective effect in PAD and other patients.69e73 There
is also evidence that serum creatinine and calculated
creatinine clearance are indicators of postopera-
tive mortality.74 Therefore, the effect of statins on renal
function following vascular surgery deserves
investigation.
National guidelines regarding the use of statins in
PAD were proposed.75 Similar international guide-
lines could result in a widely accepted strategy.
Safety of Statin Use
Perioperative statin administration in high-risk pa-
tients undergoing major elective vascular surgery
seems to be safe76 and not associated with statin-
related myopathy.77e81 A total of 885 patients (211 sta-
tin users) undergoing major elective vascular surgery
(527 AAA repair operations and 358 lower extremity
revascularization procedures) were studied. Although
maximum serum creatine kinase activities were
significantly higher in statin users compared with
non-users (301 for statin users, range 16e13 377 U/L
vs. 192 for non-users, range 8e30 390, p¼ 0.003) the
difference became non-significant ( p¼ 0.142) when
corrected for length of surgery, cardiac risk factors
and risk for myopathy. No muscular complaints or
case of rhabdomyolysis was observed in either group.
In addition, significantly fewer nonfatal MIs (15 vs. 81
and 6.7% vs. 10.8%; p< 0.01) and perioperative deaths
291Statins and Perioperative Morbidity and Mortality(5 vs. 35 and 2.1% vs. 3.9%; p< 0.01) occurred in statin
users compared with non-users. The combined
endpoint of perioperative death and MI occurred in
significantly fewer statin users compared with non-
users (8.8% vs. 14.4%; p< 0.01).
The Future
More evidence is required to confirm the benefit ob-
served in the studies described above. However, the
obvious ethical restrictions may mean that we will
never see placebo-controlled trials. One option is to
evaluate different targets and various lipid-lowering
drugs in the perioperative period to establish the op-
timal choice. For example, the cholesterol lowering
effect of statins can be extended by adding ezetimibe,
a selective cholesterol transport inhibitor.82
The low density lipoprotein cholesterol (LDL-C)
target for patients with PAD needs to be established.
For this high risk population it would be desirable
to achieve the LDL-C target defined by the European
and USA guidelines for this category (i.e. 2.5 and
2.6 mmol/l, respectively with an optional target of
1.8 mmol/l for very high risk patients).83e84
Conclusions
There is growing evidence suggesting that statin use
significantly reduces perioperative morbidity and
mortality in patients undergoing non-cardiac vascular
surgery, in a similar manner to that reported in car-
diac surgery,85e86 as well as in renal,87e88 heart,89e90
and lung91 transplantation operations. However, opti-
mal perioperative statin therapy has not been defined.
Appropriately designed trials are needed to define
optimal perioperative statin therapy in various cate-
gories of patients.
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